MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$13,818K
EPS
-$0.69
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
Research and development
8,542 7,296*
General and administrative
6,867 3,067*
Total operating expenses
15,409 10,362
Loss from operations
-15,409 -10,362*
Interest income
1,591 777*
Change in fair value of redeemable convertible preferred stock tranche liability
0 382*
Total other income (expense)
1,591 395*
Loss before income tax
-13,818 -9,967*
Federal
-0*
State
-0*
Foreign
-0*
Total current taxes
-0*
Federal
-2,177*
State
-302*
Foreign
-0*
Total deferred taxes
-2,478*
Valuation allowance
--2,477*
Income tax provision
0 0*
Net loss
-13,818 -9,967
Basic EPS
-0.69 -4.496
Diluted EPS
-0.69 -4.496
Basic Average Shares
19,927,848 2,217,104
Diluted Average Shares
19,927,848 2,217,104
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$13,818K Interest income$1,591K Loss before incometax-$13,818K Total other income(expense)$1,591K Loss from operations-$15,409K Total operatingexpenses$15,409K Research and development$8,542K General andadministrative$6,867K

SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma, Inc. (SGP)